Business
Neurochem to present at Jefferies Healthcare Conference
Neurochem to present at Jefferies Healthcare Conference.
About this update from Bluenergies Ltd.
[{"type":"text","content":"\n\n\n\nLAVAL, QC, June 26 /CNW Telbec/ - Neurochem Inc. (NASDAQ: NRMX; TSX: NRM)\nannounces today that on Wednesday, June 27, 2007, Dr. Francesco Bellini,\nChairman, President and CEO, will present Neurochem's overall strategy and\nprogress to date at the annual Jefferies Healthcare Conference to be held in\nNew York (NY). The presentation will take place at 4:10 P.M. EDT.\n\n\nThe live audio and Neurochem's presentation will be accessible at\nhttp://www.wsw.com/webcast/jeff18/nrmx. A replay of the presentation will be\navailable until July 4, 2007.\n\n\nAbout Neurochem\n\n\nNeurochem Inc. is focused on the development and commercialization of\ninnovative therapeutics to address critical unmet medical needs. Eprodisate\n(KIACTA(TM)) is currently being developed for the treatment of Amyloid A (AA)\namyloidosis, and is under regulatory review for marketing approval by the U.S.\nFood and Drug Administration, European Medicines Agency and Swissmedic.\nTramiprosate (ALZHEMED(TM)), for the treatment of Alzheimer's disease, has\ncompleted a Phase III clinical trial in North America and is currently in a\nPhase III clinical trial in Europe, while tramiprosate (CEREBRIL(TM)), for the\nprevention of Hemorrhagic Stroke caused by Cerebral Amyloid Angiopathy, has\ncompleted a Phase IIa clinical trial.\n\n\nTo Contact Neurochem\n\n\nFor additional information on Neurochem and its drug development\nprograms, please call the North American toll-free number 1-877-680-4500 or\nvisit our Web Site at www.neurochem.com.\n\n\nCertain statements contained in this news release, other than statements\nof fact that are independently verifiable at the date hereof, may constitute\nforward-looking statements. Such statements, based as they are on the current\nexpectations of management, inherently involve numerous risks and\nuncertainties, known and unknown, many of which are beyond Neurochem's\ncontrol. Such risks include but are not limited to: the impact of general\neconomic conditions, general conditions in the pharmaceutical industry,\nchanges in the regulatory environment in the jurisdictions in which Neurochem\ndoes business, stock market volatility, fluctuations in costs, and changes to\nthe competitive environment due to consolidation, that actual results may vary\nonce the final and quality-controlled verification of data and analyses has\nbeen c...